Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial

B. Hartley (Twickenham, United Kingdom), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), P. Jones (Brentford, United Kingdom), C. Crim (Research Triangle Park, NC, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Singh (Manchester, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), N. Barnes (Brentford and London, United Kingdom)

Source: International Congress 2019 – Exacerbations of airway diseases
Session: Exacerbations of airway diseases
Session type: Poster Discussion
Number: 5230
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Hartley (Twickenham, United Kingdom), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), P. Jones (Brentford, United Kingdom), C. Crim (Research Triangle Park, NC, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Singh (Manchester, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), N. Barnes (Brentford and London, United Kingdom). Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial. 5230

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: